Gentamicin-based prophylaxis in tunnelled indwelling central venous catheter limbs for haemodialysis do not result in bacterial resistances after a 9 year follow up period ଝ La profilaxis con gentamicina de las ramas del catéter venoso central permanente tunelizado en hemodiálisis no causa resistencia bacteriana durante 9 años de evolución other foci of infection. All patients with CVCB had BC+, except one with BC−. Treatment of CVCB. Gram positive organisms, vancomycin 1 g at the 1st HD and 500 mg at subsequent HDs for 3-4 weeks, or another antibiotics if appropriate; Gram negative, as indicated in the susceptibility testing, for 3-4 weeks. Key outcomes studied: ototoxicity: clinical hypoacusis and/or vertigo. Bacterial resistance to G: organisms normally sensitive to G: Gram+: coagulase negative Staphylococcus aureus sensitive to methicillin. Gram−: Escherichia coli, Proteus, Serratia, Klebsiella, Enterobacter, Pseudomona aeruginosa, etc. The minimum inhibitory concentration (MIC) of G for these bacteria is ≤4 g/mL. Resistance was detected from the results of BCs and susceptibility testing, which expressed sensitivity (S) or resistance (R) to G and the MIC value for each organism. We present the other variables studied in the results section.
Results. The mean patient age was 68 ± 29 years (21-85 years); 60 patients (48%) were women, 39 patients (31%) had diabetes. The mean time each patient remained in the study was 24 months. Thirty-eight patients were treated with prophylaxis for >30 months (30% of all study patients), mean time per patient was 50 months (31-108). On susceptibility testing, no resistance was detected in G-sensitive bacteria: the MCI was <4 g/mL, except in two cases of CVCB due to methicillinresistant Staphylococcus aureus, and one case with BC(−).
No patients had a diagnosis of ototoxicity. The mean trough level of G per patient was 0.17 g/mL (0.05-0.31). The mean G lock per limb per patient was 3 mg (2-5), equivalent to 1.1-1.7 mg/mL/limb depending on the volume of the limb according to the type of catheter.
Patients diagnosed with CVCB: 11(8.7%). Patients admitted to hospital for CVCB: 4 (3.2%). Number of CVCB/CVC/1000 days: 0.17. CVC removed due to CVCB: 3 patients (2.4%). Mortality due to CVCB: 1 (0.8%). Number of CVCB: 15, Staphylococcus aureus: 8; Staphylococcus epidermidis: 4; Escherichia coli: 1; Streptococcus bovis: 1, and BC(−): 1. CVC was removed due to recurrent CVCB in one patient, for failure to improve clinically of in one patient, and due to BC(−) in one patient with clinical remission. There were no other CVCB complications (endocarditis, spondylodiscitis), except in one patient who died due to sepsis.
Discussion. The scientific literature demonstrates that in HD patients, prophylaxis with post-HD antibiotic locking of CVC limbs, including G, reduces morbidity and mortality from bacterial infection associated with CVCB (number of CVCB/CVC/1000 days, mortality and hospital admission due to CVCB) compared with patients with heparin lock alone. 3 Bacterial resistance to G has been reported. 4 However, our experience since July 2003 in patients with CVC attending to the unit and treated with G locking in doses lower than those given in other units (a detail we consider fundamental due to iatrogenic effects), no bacterial resistance or ototoxicity was demonstrated after 9 years of follow-up. 3 Having seen our results, we must refer to the publication by Beathar and Urbanes 1 in which they rate the quality of care of a HD unit according to the number of CVCB/CVC/1000 days it obtains when complete asepsis is employed, an excellent result being a value ≤1. In our case, the practice of complete asepsis + prophylaxis meant that the number of CVCB/CVC/1000 days was 0.17. Although we are unable to compare another study, in 9 years, to obtain a mortality, removal of CVC, and hospital admission due to CVCB of 0.8%, 2.4%, and 3.2%, respectively, is an appreciable standard, obtained thanks to G prophylaxis + universal asepsis. This is further underlined by the absence of endocarditis or spondylodiscitis, except for one patient who died due to sepsis. Strict complete asepsis 5 for all handling procedures of CVC is integral to prophylaxis in reducing morbidity and mortality from bacterial infection associated with CVCB.
Conclusions. This prospective observational study of 9 years' duration in 126 HD patients with a CVC showed: (1) Prophylaxis with intraluminal G locking in CVC limbs does not cause antibiotic resistance in microorganisms sensitive to the antibiotic. (2) There were no diagnoses of clinical ototoxicity, and (3) Prophylaxis with administration of low-dose G (compared with higher doses in other studies) 3 can result in the absence of resistance and ototoxicity. r e f e r e n c e s
